Attached files

file filename
EX-99.1 - EX-99.1 - Savara Incexhibit1.htm






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   December 1, 2011

ADVENTRX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-32157 84-1318182
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
12390 El Camino Real, Suite 150, San Diego, California   92130
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   858-552-0866

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On December 1, 2011, ADVENTRX Pharmaceuticals, Inc. issued a press release announcing that it met with the U.S. Food and Drug Administration to review development plans for one of its lead product candidates, ANX-188 (purified poloxamer 188). The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ADVENTRX Pharmaceuticals, Inc.
December 2, 2011   By:   /s/ Patrick L. Keran
        Name: Patrick L. Keran
        Title: President and Chief Operating Officer

Exhibit Index

Exhibit No.   Description

  Press release, dated December 1, 2011